Notícias

Healthcare stocks rose late Monday afternoon with the NYSE Healthcare Index increasing 0.6% and the

CagriSema beat 5-milligram tirzepatide in diabetes--not Lilly's full dosing range or broader obesity franchise.

A three-week study produced rapid symptom improvement, but regulatory approval and commercial conversion remain ahead.

Smart ring maker Oura is seeking a valuation of as much as $15.6 billion in an IPO that could test investor appetite for a new wave of fall listings.

The top healthcare stock has been underperforming the market, and its returns haven't been as impressive as in recent years.

Oura, a smart ring maker, said Monday it launched a US initial public offering of 50 million common

Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index increasing 0.5% and the Stat

Eli Lilly is posting 48% revenue growth while its stock sits nearly flat for the year, and that disconnect points to something Wall Street may be mispricing entirely.

CEO Dave Ricks also broke ground Monday on a $6.5 billion manufacturing plant in Houston that Lilly expects will be operational by 2030

Oura is offering 50 million shares at $40 to $44 each, targeting a fully diluted valuation of $15.62 billion

Eli Lilly (LLY) is back in focus after the U.S. Food and Drug Administration granted full approval for Inluriyo, used with Verzenio in certain ESR1 mutated metastatic breast cancer patients. Eli Lilly’s share price has eased over the past month, with a 30-day share price return of 8.16% in the red. However, the 1-year total shareholder return of 53.68% and roughly 4x gain over five years point to momentum that remains firmly intact. Compare Eli Lilly’s oncology and obesity story with other...

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...

Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth

All three major US stock indexes were up in late-morning trading Monday, as oil prices and Treasury

The Danish drugmaker fell as much as 9% after its Capital Markets Day promised new blockbusters and broader growth but failed to give investors the certainty they wanted beyond Wegovy and Ozempic.

Key Takeaways; Psychedelic Sector Optimi Health Plans to Initiate Phase 3 Clinical Trial Evaluating MDMA Therapy for Individuals with PTSD Eli Lilly Completed $2.8 Billion Acquisition of AtaiBeckley, Expanding its Mental Health Pipeline Definium’s Phase 3 Panorama Trial Delivered Positive Results for DT120 in Generalized Anxiety Disorder Psyence BioMed Established Texas Entity to Advance U.S. […]

On this episode of Stock Movers: - Novo Nordisk (NVO) shares are lower as it disappointed investors hoping for concrete turnaround plans from Chief Executive Officer Mike Doustdar after losing its lead in the obesity market to Eli Lilly & Co. The company pledged to launch more than five blockbusters and deliver more than $23 billion in new sales in coming years, but investors are selling shares due to lack of concrete news. - Arhaus (ARHS) is moving after Jefferies upgraded the furniture company to buy from hold, writing that it has "newfound optimism on the retailer's strategy to elevate brand awareness" and improve market share. - Accenture (ACN) is up on news Anthropic is partnering with Accenture to test the safety of its advanced artificial intelligence models by embedding evaluators from the consulting firm directly within its operations.

Pfizer Reveals Surprise HHS Revenue-Sharing Terms in Overseas Drug Pricing Deal

NVIDIA and Eli Lilly both shattered expectations this quarter, but picking the better stock for the next decade means choosing between two very different growth machines at very different levels of risk.

Novo Nordisk (NVO) stock is dipping after the company's outlook disappointed investors. Yahoo Finance Executive Editor Brian Sozzi shares his thoughts on the stock, the company's trajectory, and where Eli Lilly (LLY) fits into the equation.

Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.

Oura, the Finnish maker of smart health-tracking rings, disclosed plans on Monday to sell 50 million shares priced between $40 and $44 each in its initial public offering. The offering could raise as much as $2.2 billion and value the company at up to $14.1 billion based on its outstanding...

Novo Nordisk took the stage at its own capital markets day and said something that sent its stock tumbling 7%, yet its closest rivals barely flinched. What the company revealed about its future tells investors exactly how much trouble the Ozempic empire may be in.

The 8:30 panel featuring Yahoo Finance Host Julie Hyman, Senior Autos Reporter Pras Subramanian, and Breaking Business News Reporter Jake Conley examines Novo Nordisk’s (NVO ) long-term targets as shares slide amid intensifying competition from Eli Lilly (LLY ).

Novo Nordisk plans to launch at least five multi-blockbuster drugs by 2030 and is targeting pipeline drug sales of $23 billion by 2035.

The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity

Oura and some of its shareholders plan to offer 50 million common shares at an estimated price of $4

Investing.com -- Oura is seeking to offer 50 million shares priced between $40 and $44 each, the company disclosed in a Monday SEC filing. The smart ring maker plans to offer 13.5 million shares, while existing stockholders will sell 36.5 million shares.

Novo Nordisk’s long-term growth targets failed to ease investor concerns over Eli Lilly’s obesity-drug lead, CagriSema’s comparative performance and upcoming semaglutide patent expirations.